Literature DB >> 15149316

A large tandem duplication within the COL4A5 gene is responsible for the high prevalence of Alport syndrome in French Polynesia.

Christelle Arrondel1, Georges Deschênes, Yannick Le Meur, Amandine Viau, Christophe Cordonnier, Alain Fournier, Stephane Amadeo, Marie-Claire Gubler, Corinne Antignac, Laurence Heidet.   

Abstract

A large tandem duplication within the COL4A5 gene is responsible for the high prevalence of Alport syndrome in French Polynesia. Background. The prevalence of X-linked Alport syndrome, a progressive inherited nephropathy associated with mutations in the type IV collagen gene COL4A5, is remarkably high in French Polynesia. Methods. A vast clinical, genealogic, and molecular study was undertaken in Polynesia, based on public records, patients' interviews, linkage analysis, and mutation screening. Results and Conclusions. We show that the high frequency of Alport syndrome in this region is due to a founder mutation that occurred onto a common haplotype shared by affected and unaffected individuals, the presence of which precludes indirect molecular diagnosis. We have characterized the mutation as a tandem duplication of 35 COL4A5 exons, resulting in a approximately 65% increase in the length of the collagenous domain of the alpha 5(IV) chain, which is still able to assemble into type IV collagen network as shown by immunofluorescence analysis. That mutation is associated with severe and highly penetrant ocular symptoms and with uniformly thin glomerular basement membrane (GBM) in male adult patients. However, the rate of progression of the renal disease is very variable from one male patient to another, demonstrating the importance of strong modifier factors. Our results suggest that the 20% to 50% of "missing"COL4A5 mutations in X-linked Alport syndrome may be rearrangements similar to that reported here, which was not detectable by sequencing of either individual COL4A5 exons or overlapping cDNA fragments. Finally, we provide the basis for a polymerase chain reaction (PCR) assay that accurately identifies female carriers and allows adequate genetic counseling in this population.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15149316     DOI: 10.1111/j.1523-1755.2004.00622.x

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  12 in total

1.  Alport syndrome caused by inversion of a 21 Mb fragment of the long arm of the X-chromosome comprising exon 9 through 51 of the COL4A5 gene.

Authors:  Jens Michael Hertz; Ulf Persson; Inger Juncker; Mårten Segelmark
Journal:  Hum Genet       Date:  2005-10-28       Impact factor: 4.132

2.  Improving mutation screening in familial hematuric nephropathies through next generation sequencing.

Authors:  Vincent Morinière; Karin Dahan; Pascale Hilbert; Marieline Lison; Said Lebbah; Alexandra Topa; Christine Bole-Feysot; Solenn Pruvost; Patrick Nitschke; Emmanuelle Plaisier; Bertrand Knebelmann; Marie-Alice Macher; Laure-Hélène Noel; Marie-Claire Gubler; Corinne Antignac; Laurence Heidet
Journal:  J Am Soc Nephrol       Date:  2014-05-22       Impact factor: 10.121

3.  COL4A3/COL4A4 mutations and features in individuals with autosomal recessive Alport syndrome.

Authors:  Helen Storey; Judy Savige; Vanessa Sivakumar; Stephen Abbs; Frances A Flinter
Journal:  J Am Soc Nephrol       Date:  2013-09-19       Impact factor: 10.121

4.  Diagnosis of Alport syndrome--search for proteomic biomarkers in body fluids.

Authors:  Michael Pohl; Karin Danz; Oliver Gross; Ulrike John; Johannes Urban; Ludwig Patzer; Sandra Habbig; Markus Feldkötter; Oliver Witzke; Mario Walther; Heidrun Rhode
Journal:  Pediatr Nephrol       Date:  2013-06-23       Impact factor: 3.714

5.  Targeted genome editing in vivo corrects a Dmd duplication restoring wild-type dystrophin expression.

Authors:  Eleonora Maino; Daria Wojtal; Sonia L Evagelou; Aiman Farheen; Tatianna W Y Wong; Kyle Lindsay; Ori Scott; Samar Z Rizvi; Elzbieta Hyatt; Matthew Rok; Shagana Visuvanathan; Amanda Chiodo; Michelle Schneeweiss; Evgueni A Ivakine; Ronald D Cohn
Journal:  EMBO Mol Med       Date:  2021-03-16       Impact factor: 12.137

6.  A Novel Mutation in a Kazakh Family with X-Linked Alport Syndrome.

Authors:  Barshagul T Baikara; Elena V Zholdybayeva; Saule E Rakhimova; Nazym B Nigmatullina; Kuvat T Momynaliev; Yerlan M Ramanculov
Journal:  PLoS One       Date:  2015-07-13       Impact factor: 3.240

7.  A novel COL4A5 mutation identified in a Chinese Han family using exome sequencing.

Authors:  Xiaofei Xiu; Jinzhong Yuan; Xiong Deng; Jingjing Xiao; Hongbo Xu; Zhaoyang Zeng; Liping Guan; Fengping Xu; Sheng Deng
Journal:  Biomed Res Int       Date:  2014-07-06       Impact factor: 3.411

8.  Analysis of NHEJ-Based DNA Repair after CRISPR-Mediated DNA Cleavage.

Authors:  Beomjong Song; Soyeon Yang; Gue-Ho Hwang; Jihyeon Yu; Sangsu Bae
Journal:  Int J Mol Sci       Date:  2021-06-15       Impact factor: 5.923

9.  X-Linked and Autosomal Recessive Alport Syndrome: Pathogenic Variant Features and Further Genotype-Phenotype Correlations.

Authors:  Judith Savige; Helen Storey; Hae Il Cheong; Hee Gyung Kang; Eujin Park; Pascale Hilbert; Anton Persikov; Carmen Torres-Fernandez; Elisabet Ars; Roser Torra; Jens Michael Hertz; Mads Thomassen; Lev Shagam; Dongmao Wang; Yanyan Wang; Frances Flinter; Mato Nagel
Journal:  PLoS One       Date:  2016-09-14       Impact factor: 3.240

10.  Intracerebral hemorrhage in a neonate with an intragenic COL4A2 duplication.

Authors:  Saskia Koene; Cacha M P C D Peeters-Scholte; Jeroen Knijnenburg; Linda S de Vries; Phebe N Adama van Scheltema; Marije E Meuwissen; Sylke J Steggerda; Gijs W E Santen
Journal:  Am J Med Genet A       Date:  2020-11-28       Impact factor: 2.578

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.